Sumitomo became the strategic shareholder with shareholding of 29% held in C&O. C&O Board of Directors has been restructured and Sumitomo Corporation will appoint three directors to the C&O Board.
MoreThe Chinese government has recently included four new drug projects being developed by C&O in the major scientific and technological projects for “major new drug initiation”, the first program established by the Chinese government in the 11th Five-Ye
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mail[email protected]
Official WeChat account Mobile page